141 related articles for article (PubMed ID: 32798414)
1. [Outcomes of DNMT3A
Chen YY; Shi R; Guo SQ; Zhang YX; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1292-1297. PubMed ID: 32798414
[TBL] [Abstract][Full Text] [Related]
2. [Clinical Efficacy and Prognostic Factors of Decitabine for Treatment of Myelodysplastic Syndrome].
Bao ZH; Zhao HG; Yu HE
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1702-1707. PubMed ID: 30501707
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of Decitabine Rigimen and Traditional Chemotherapy Regimen in Treatment of Patients with Intermediate or High-Risk Myelodysplastic Syndrome].
Zhang QP; Han YS; Wan X; Sun GY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):197-201. PubMed ID: 29397843
[TBL] [Abstract][Full Text] [Related]
4. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
5. [Platelet Count Doubling after One Course of Demethylated Drug Therapeutic Predicts the Treatment Response and Efficacy of Patients with Myelodysplastic Syndrome].
Hui H; Yu HY; Li DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):184-189. PubMed ID: 38387919
[TBL] [Abstract][Full Text] [Related]
6. [Clinical Efficacy Comparison of Ultralow Dose of Decitabine and Cyclosporine on Low-risk and Intermediate-risk Type 1 of Myelodysplastic Syndrome].
Luo X; Wu H; Ding Y; Chen YH; Liang AB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):510-4. PubMed ID: 27151020
[TBL] [Abstract][Full Text] [Related]
7. [Clinical observation of decitabine-treating patients with myelodysplastic syndrome and acute myeloid leukemia].
Yang H; Zhu HY; Jiang MM; Wang QS; Han XP; Huang WR; Jing Y; Wang SH; Zhang SS; Mei JH; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):121-5. PubMed ID: 23484704
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes].
Zhang YP; Wu WZ; Cui GX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1341-4. PubMed ID: 25338585
[TBL] [Abstract][Full Text] [Related]
9. [A preliminary study on the outcome of lower-risk myelodysplastic syndrome by low-dose decitabine].
Ye L; Ren YL; Xie LL; Luo YW; Lin PP; Zhou XP; Ma LY; Mei C; Xu WL; Wei JY; Jiang HF; Zhang LM; Zeng H; Tong HY
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):307-312. PubMed ID: 28468092
[No Abstract] [Full Text] [Related]
10. [Clinical Comparation of Two Kinds of Chemotherapy Regimens in the Treatment of Patients with MDS-RAEB/AML-MRC].
Wu XF; Li TT; Sun L; Wang LJ; Ran XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):894-898. PubMed ID: 32552954
[TBL] [Abstract][Full Text] [Related]
11. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
[TBL] [Abstract][Full Text] [Related]
12. [Predict response to decitabine in patients with myelodysplastic syndrome and related neoplasms].
Zhao YS; Guo J; Xu F; Wu D; Wu LY; Song LL; Xiao C; Li X; Chang CK
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):124-128. PubMed ID: 28279036
[No Abstract] [Full Text] [Related]
13. [The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
Gao S; Qiu H; Jin Z; Tang X; Fu Z; Ma X; Han Y; Chen S; Sun A; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):961-5. PubMed ID: 25417868
[TBL] [Abstract][Full Text] [Related]
14. [Effects of Low-Dose Decitabine on Soluble CD44, GDF11 Levels and Hematopoietic Function in Elderly Patients with MDS].
Guo SQ; Shi R; Chen YY; Liu S; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):509-514. PubMed ID: 30998162
[TBL] [Abstract][Full Text] [Related]
15. [Clinical Efficacy of Low-Dose Decitabine alone for Treatment of Myelodysplastic Syndrome].
Shi R; Guo SQ; Chen YY; Liu S; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1568-1573. PubMed ID: 31607313
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
17. Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome.
Jung HA; Jung CW; Jang JH
Korean J Intern Med; 2021 Mar; 36(2):413-423. PubMed ID: 33086776
[TBL] [Abstract][Full Text] [Related]
18. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
19. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
20. Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study.
Lee BH; Kang KW; Jeon MJ; Yu ES; Kim DS; Choi H; Lee SR; Sung HJ; Kim BS; Choi CW; Park Y
Sci Rep; 2020 Jan; 10(1):39. PubMed ID: 31913293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]